BioLife Solutions’ (BLFS) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of BioLife Solutions (NASDAQ:BLFS) in a research report report published on Tuesday morning,Benzinga reports. HC Wainwright currently has a $30.00 price target on the medical equipment provider’s stock. HC Wainwright also issued estimates for BioLife Solutions’ Q2 2025 earnings at ($0.04) EPS, Q4 2025 earnings at ($0.04) EPS, Q1 2026 earnings at $0.00 EPS, Q2 2026 earnings at $0.00 EPS, Q3 2026 earnings at $0.03 EPS, Q4 2026 earnings at $0.00 EPS and FY2026 earnings at $0.03 EPS.

Separately, StockNews.com downgraded shares of BioLife Solutions from a “hold” rating to a “sell” rating in a report on Thursday, April 24th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $31.17.

BioLife Solutions Stock Performance

Shares of NASDAQ:BLFS opened at $21.99 on Tuesday. The company has a market capitalization of $1.04 billion, a price-to-earnings ratio of -20.75 and a beta of 2.01. The firm’s 50 day simple moving average is $23.58 and its 200 day simple moving average is $25.29. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.78 and a quick ratio of 1.78. BioLife Solutions has a fifty-two week low of $18.70 and a fifty-two week high of $29.55.

BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings results on Thursday, May 8th. The medical equipment provider reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.07. The business had revenue of $23.94 million for the quarter, compared to the consensus estimate of $22.22 million. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. As a group, sell-side analysts forecast that BioLife Solutions will post -0.3 earnings per share for the current year.

Insider Activity at BioLife Solutions

In other BioLife Solutions news, CMO Todd Berard sold 1,577 shares of BioLife Solutions stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $25.00, for a total transaction of $39,425.00. Following the completion of the transaction, the chief marketing officer now directly owns 104,961 shares of the company’s stock, valued at $2,624,025. The trade was a 1.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Sarah Aebersold sold 2,695 shares of BioLife Solutions stock in a transaction on Monday, March 17th. The stock was sold at an average price of $25.44, for a total transaction of $68,560.80. Following the transaction, the insider now directly owns 43,165 shares of the company’s stock, valued at approximately $1,098,117.60. This trade represents a 5.88% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 71,696 shares of company stock valued at $1,665,094. 2.20% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On BioLife Solutions

A number of institutional investors have recently modified their holdings of the business. D.A. Davidson & CO. raised its stake in BioLife Solutions by 1.3% in the fourth quarter. D.A. Davidson & CO. now owns 41,179 shares of the medical equipment provider’s stock valued at $1,069,000 after purchasing an additional 519 shares in the last quarter. Sei Investments Co. raised its stake in BioLife Solutions by 0.5% during the first quarter. Sei Investments Co. now owns 117,999 shares of the medical equipment provider’s stock worth $2,695,000 after acquiring an additional 547 shares in the last quarter. Rhumbline Advisers raised its stake in BioLife Solutions by 0.7% during the first quarter. Rhumbline Advisers now owns 83,227 shares of the medical equipment provider’s stock worth $1,901,000 after acquiring an additional 566 shares in the last quarter. GAMMA Investing LLC raised its stake in BioLife Solutions by 18.6% during the first quarter. GAMMA Investing LLC now owns 4,223 shares of the medical equipment provider’s stock worth $96,000 after acquiring an additional 663 shares in the last quarter. Finally, 1620 Investment Advisors Inc. raised its stake in BioLife Solutions by 41.7% during the fourth quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider’s stock worth $60,000 after acquiring an additional 675 shares in the last quarter. Institutional investors own 93.24% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.